KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer

(2015) Sunny Guin et al.   ACTA PHARMACOLOGICA SINICA

KRAS Mutations in Lung Adenocarcinoma: Molecular and Epidemiological Characteristics, Methods for Detection, and Therapeutic Strategy Perspectives

(2015) N. Guibert et al.   CURRENT MOLECULAR MEDICINE

Endoscopic Ultrasound–guided Fine-Needle Aspiration Biopsy Coupled With a KRAS Mutation Assay Using Allelic Discrimination Improves the Diagnosis of Pancreatic Cancer

(2015) Barbara Bournet et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Pancreatic cancer, treatment options, and GI-4000

(2015) Marion L Hartley et al.   Human Vaccines & Immunotherapeutics

Pancreatic Adenocarcinoma

(2015) David P. Ryan et al.   NEW ENGLAND JOURNAL OF MEDICINE

A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

(2014) Jeffrey R. Infante et al.   EUROPEAN JOURNAL OF CANCER

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy

(2014) Mihaly Cserepes et al.   EUROPEAN JOURNAL OF CANCER

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

(2014) Benjamin Izar et al.   Journal of Thoracic Oncology

KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma

(2014) Bruno V. Sinn et al.   PANCREAS

Targeting pathways downstream of KRAS in lung adenocarcinoma

(2014) Zehua Zhu et al.   PHARMACOGENOMICS

Roles for KRAS in Pancreatic Tumor Development and Progression

(2013) Marina Pasca di Magliano et al.   GASTROENTEROLOGY

KRASMutation: Should We Test for It, and Does It Matter?

(2013) Patrick J. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

(2013) Stefan Boeck et al.   JOURNAL OF GASTROENTEROLOGY

Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival

(2013) Sang Hyun Shin et al.   PANCREAS

Targeting the Ras–ERK pathway in pancreatic adenocarcinoma

(2012) Cindy Neuzillet et al.   CANCER AND METASTASIS REVIEWS

Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples

(2012) Audrey Didelot et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

(2012) Takeshi Ogura et al.   JOURNAL OF GASTROENTEROLOGY

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Genetic and Epigenetic Alterations in Pancreatic Carcinogenesis

(2011) Yannick Delpu et al.   CURRENT GENOMICS

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

(2011) György Bodoky et al.   INVESTIGATIONAL NEW DRUGS

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

(2011) S. T. Kim et al.   MOLECULAR CANCER THERAPEUTICS

KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

(2011) F. Kullmann et al.   ONCOLOGY

EGFR and KRAS Mutational Analysis and Their Correlation to Survival in Pancreatic and Periampullary Cancer

(2011) Melissa Oliveira-Cunha et al.   PANCREAS

The Role of Phosphatidylinositol 3-Kinase Signaling Pathways in Pancreatic Cancer

(2011) Chen Sun et al.   PANCREATOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

(2010) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

(2010) S. A. Forbes et al.   NUCLEIC ACIDS RESEARCH

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Endoscopic ultrasound-guided fine-needle aspiration biopsy coupled withKRASmutation assay to distinguish pancreatic cancer from pseudotumoral chronic pancreatitis

(2009) B. Bournet et al.   ENDOSCOPY

Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics

(2009) Vassiliki Kotoula et al.   PLoS One

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers

(2008) Antoun Toubaji et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Loss of Heterozygosity Predicts Poor Survival After Resection of Pancreatic Adenocarcinoma

(2008) Jan Franko et al.   JOURNAL OF GASTROINTESTINAL SURGERY